RAPID-CHF Study Overview

Results of the RAPID-CHF Study

The RAPID-CHF study was a randomized controlled trial of 40 heart failure patients in six hospitals in Minneapolis/St. Paul. The patients were divided into two groups of 20: one group received a single eight-hour session of ultrafiltration, and the other group received the standard treatment for fluid overload in heart failure patients, which included 24 hours of diuretic treatment.

After 24 hours, significantly more excess fluid was removed from the patients who had received ultrafiltration.

Unlike diuretic treatment, ultrafiltration was not associated with significant changes in heart rate, blood pressure or electrolytes (small molecules, such as sodium, in our bodily fluids). At 38 hours, shortness of breath and other symptoms of fluid overload (such as swelling of the legs, feet or abdomen) were significantly improved in patients in the ultrafiltration group.

The researchers concluded that ultrafiltration is safe, well-tolerated and associated with effective fluid removal and relief of fluid-overload symptoms. They also concluded that there's no need to delay ultrafiltration therapy until diuretics fail. Patients who received ultrafiltration had an increased responsiveness to subsequent diuretic therapy and increased sodium excretion, despite decreasing doses of diuretics.

To learn more about fluid overload and ultrafiltration, take a gander at the links on the next page.

More to Explore